Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer Highlights der ASCO- und ESMO-Jahrestagungen 2021 zur Strahlentherapie von Kopf-Hals-Tumoren

Hecht M, von der Grün J, Semrau S, Müller S, Weissmann T, Gaipl U, Iro H, Fietkau R, Gostian AO (2022)

Publication Type: Journal article, Review article

Publication year: 2022

Journal

HNO Springer Verlag

DOI: 10.1007/s00106-022-01150-4

Abstract

At this year’s annual meetings of the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), several studies on radiotherapy of locally advanced head and neck cancer were presented. For the indication of definitive radiochemotherapy, particularly the administration of immune checkpoint inhibitors concomitant to radiotherapy was investigated. In the phase III GORTEC-REACH trial, combined inhibition of epidermal growth factor receptor (EGFR) and programmed death-ligand (PD-L1) concomitant to radiotherapy of locally advanced head and neck cancer was inferior to platinum-based chemoradiotherapy. However, this therapeutic approach may be more efficient than radiotherapy with simultaneous EGFR inhibition alone. The concept of the phase II CheckRad-CD8 trial with induction chemoimmunotherapy followed by chemotherapy-free radioimmunotherapy after appropriate patient selection also proved to be highly efficient. In initial phase II trials, dose de-escalation of radiotherapy seems feasible for HPV-positive oropharyngeal cancer after appropriate patient selection both postoperatively (ECOG-ACRIN E3311 trial) and after induction therapy (Optima II trial). However, dose de-escalation should currently not be performed outside of clinical trials. In addition, first studies indicate a benefit of functional imaging (diffusion-weighted magnetic resonance imaging [MRI] or F‑fluoromisonidazole positron-emission tomography [FMISO-PET]) to establish personalized dose concepts in radiotherapy.

Authors with CRIS profile

Markus Hecht Department of Radiation Oncology Sabine Semrau Medizinische Fakultät Thomas Weissmann Department of Radiation Oncology Udo Gaipl Department of Radiation Oncology Heinrich Iro Lehrstuhl für Hals-, Nasen- und Ohrenheilkunde Rainer Fietkau Lehrstuhl für Strahlentherapie Antoniu-Oreste Gostian Department of Otorhinolaryngology – Head and Neck Surgery

Involved external institutions

Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE)

How to cite

APA:

Hecht, M., von der Grün, J., Semrau, S., Müller, S., Weissmann, T., Gaipl, U.,... Gostian, A.-O. (2022). Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer Highlights der ASCO- und ESMO-Jahrestagungen 2021 zur Strahlentherapie von Kopf-Hals-Tumoren. HNO. https://doi.org/10.1007/s00106-022-01150-4

MLA:

Hecht, Markus, et al. "Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer Highlights der ASCO- und ESMO-Jahrestagungen 2021 zur Strahlentherapie von Kopf-Hals-Tumoren." HNO (2022).

BibTeX: Download